ClinicalTrials.gg
CompletedNCT00627003Updated Apr 25, 2011

A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS

A Phase 3 interventional study of Cabergoline and Placebo in Restless Legs Syndrome, sponsored by Pfizer. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-04-25.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of cabergoline compared with placebo on periodic leg movements (PLMS) arousl index and sleep efficiency in patients with RLS. Also, additional objective and subjective sleep parameters and quality of life will be assessed.

02

Conditions studied

  • Restless Legs Syndrome
03

In context

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

This study's enrollment of 43 is below the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.

Browse Restless Legs Syndrome studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Idiopathic RLS
  • Moderate to severe symptoms as indicated by an IRLS total score greater than or equal to 10 and a severity at night score of greater than or equal to 4
  • In a baseline polysomnography, patients had to have periodic leg movements during sleep arousal index greater than 5/hour of total sleep time

Exclusion criteria

Exclusion Criteria:

  • Patients suffering from seconadry RLS, due to causes such as iron deficiency or renal disease, or suffering from secondary RLS while taking drugs suspected of causing secondary forms of RLS
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    1

    Drug: Cabergoline

  • Experimental
    2

    Other: Placebo

Interventions

  • Cabergoline oral tablets administered once daily in the evening: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14, followed by a stable dose for an additional 3 weeks

  • OtherPlacebo

    Placebo oral tablets administered daily for 5 weeks

06

What researchers measure

Primary outcomes

  1. Sleep efficiency

    Time frame: Week 5

  2. PLMS-arousal index (PLMS-AI)

    Time frame: Week 5

Secondary outcomes

  1. Sleep Questionnaire Form A

    Time frame: Weeks 2 and 5

  2. Quality of Life for RLS questionnaire

    Time frame: Weeks 2 and 5

  3. Clinical Global Impressions

    Time frame: Weeks 2 and 5

  4. Safety including type and frequency of adverse events, changes in laboratory data and abnormalities observed in electrocardiography

    Time frame: Weeks 2 and 5

  5. Total score of the severity rating scale of the International RLS (IRLS) Study Group

    Time frame: Weeks 2 and 5

  6. RLS-6 severity scales

    Time frame: Weeks 2 and 5

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002 and a completion of May 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2008
First posted
Feb 29, 2008
Start
Nov 2002
CompletionActual
May 2003
Last update
Apr 25, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00627003
Lead sponsor
Pfizer
First posted
Feb 29, 2008
Start date
Nov 2002
Completion
May 2003
Last update
Apr 25, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabergoline

Start the discussion